Table 1

Definitions of the LLDAS criteria used in the two post hoc studies

Parodis et al 1 Oon et al 2
1. SLEDAI-2K score≤4 with no activity in the renal descriptors (proteinuria, pyuria, haematuria and cellular casts), no pleurisy, no pericarditis and no fever.1. SLEDAI-2K score≤4 with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis an fever) and no haemolytic anaemia or gastrointestinal activity.
2. No new features of SLE activity, defined as no new moderate or severe flare according to the SELENA-SLEDAI Flare Index compared with baseline.2. No new features of lupus disease activity, defined as no new SELENA-SLEDAI item score>0 and no new BILAG activity compared with the previous assessment.
3. SELENA-SLEDAI PGA score≤1 (scale: 0–3).3. SELENA-SLEDAI PGA score≤1 (scale: 0–3).
4. Daily prednisone or prednisone equivalent dose≤7.5 mg.4. Current prednisone equivalent dose≤7.5 mg/day.
5. Standard maintenance dosages of immunosuppressive drugs and approved biologic agents.
  • All criteria had to be met for attainment of LLDAS.

  • . BILAG, British Isles Lupus Assessment Group; LLDAS, Lupus Low Disease Activity State; PGA, physician’s global assessment; SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.